• 1999.09—2004.07  北华大学医学检验专业本科生

• 2004.09—2007.07  北华大学临床检验专业硕士生

• 2011.09—2014.07  杏鑫娱乐病原生物学专业博士研究生

• 2007.08—2011.07  浙江省台州医院

• 2014.08—2016.09  上海市疾病预防控制中心

• 2016.10—2019.10  杏鑫博士后

• 2019.11—至今    杏鑫青年副研究员

• 2013➛，“一健康”基金，杏鑫娱乐上海医杏鑫

• 生物医药领域，新发与再现病毒感染的病毒融合/进入抑制剂

• 2018♧，国家自然科学基金青年项目👧🏽，“HIV病毒NHR区下游新靶点机制研究”🤷🏻，主持

本科生课程：

• 医学微生物学本科教学实验课

1. Xu W#, Cong Z#, Duan Q#, Wang Q, Su S, Wang R, Lu L*, Xue J*, Jiang S*. A protein-based, long-acting HIV-1 fusion inhibitor with an improved pharmacokinetic profile. Pharmaceuticals 2022, 15(4), 424

2. Duan Q, Xia S, Jiao F, Wang Q, Wang R, Lu L*, Jiang S*, Xu W*. A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life. Viruses 2022, 14(4), 655

3. Liu Z#, Zhou J#, Xu W#, Deng W#, Wang Y#, Wang M#, Wang Q, Hsieh M, Dong J, Wang X, Huang W, Xing L, He M, Tao C, Xie Y, Zhang Y*, Wang Y*, Zhao J*, Yuan Z*, Qin C*, Jiang S*, Lu L*. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Res. 2022 Mar;32(3):269-287.

4. Xu W, Su S, Jiang S. Ring vaccination of COVID-19 vaccines in medium- and high-risk areas of countries with low incidence of SARS-CoV-2 infection. Clin Transl Med. 2021 Feb;11(2):e331.

5. Xu W, Pu J, Su S, Hua C, Su X, Wang Q, Jiang S*, Lu L*. Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41. AIDS. 2019 Aug 1;33(10):1545-1555.

6. Xu W#; Pu J #; Su S#; Hua C; Su Xiaojie; Wang Qian; Jiang Shibo*; Lu Lu*; Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41, AIDS, 2019 33(10):1545-1555.

7. Bi W#, Xu W#, Cheng L, Xue J, Wang Q, Yu F, Xia S, Wang Q, Li G, Qin C, Lu L*, Su L*, Jiang S*. IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. PLoS Pathog. 2019 Dec 5;15(12):e1008082.

8. Xu W, Xia S, Pu J, Wang Q, Li P, Lu L*, Jiang S*. The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. Front Microbiol. 2018 Nov 6;9:2643.

9. Xu W#, Wang Q#, Yu F, Lu L*, Jiang S*. Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs. J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):1-6.

10. Xu W#, Lu L#, Shen B, Li J, Xu J, Jiang S*. Serological investigation of subclinical influenza A(H7H9) infection among healthcare and non-healthcare workers in Zhejiang Province, China. Clin Infect Dis. 2013 Sep;57(6):919-21

1. 一种抑制艾滋病病毒感染活性的多肽及其相关噬菌体 (已授权🧾🟫：ZL201210379629.2)

2. 一种长效HIV-1膜融合抑制剂 (已授权：ZL201310655778.1)

3. 马来酸卡比沙明在制备抗流感病毒药物中的应用 (已授权：ZL201810996687.7)

4. 一种长效HIV‐1膜融合抑制剂 (已授权🛌🏿🐃：ZL201310655778.1)